<DOC>
	<DOCNO>NCT02920827</DOCNO>
	<brief_summary>The propose study single center , double-blind placebo-controlled trial ass safety tolerability dapivirine ring compare placebo ring inserted 28 day 16 healthy , HIV-negative woman .</brief_summary>
	<brief_title>Safety Pharmacokinetic Trial Healthy HIV-Negative Women Assess Delivery Dapivirine From Vaginal Ring</brief_title>
	<detailed_description>The objective trial evaluate feasibility use platinum-catalyzed matrix vaginal ring , contain 25 mg dapivirine , deliver investigational product 28 continuous day . The specific objective : 1 . Assess safety tolerability vaginal ring contain dapivirine , use continuously 28 day , compare placebo ring 2 . Assess dapivirine concentration plasma , 28 day ' use silicone elastomer matrix vaginal ring contain dapivirine 3 . Assess dapivirine concentration vaginal fluid , 28 day ' use silicone elastomer matrix vaginal ring contain dapivirine . Safety evaluate clinical evaluation , clinical laboratory test result adverse event ( AEs ) . The pharmacokinetic ( PK ) evaluation make base systemic absorption plasma concentration local disposition vaginal fluid concentration .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>female 18 40 year age , inclusive willing able give write , informed consent available visit consent follow procedure schedule trial healthy , base medical history , vital sign , physical examination , urinalysis ( dipstick microscopy ) , laboratory evaluation genital infection ( gonorrhea , chlamydia trichomonas ) , laboratory evaluation hematology biochemistry HIVnegative , determine HIV test screen willing abstain sexual activity duration period ring use stable form contraception , define stable oral contraceptive regimen least two month prior enrollment ; OR transdermal contraceptive patch least three month prior enrollment ; OR longacting progestin least six month prior enrollment ; OR intrauterine device ( IUD ) insert ( vaginal gynecological complaint associate use ) least three month prior enrollment ; OR undergo surgical sterilization least three month prior enrollment ; AND willing use oral contraceptive , necessary , avoid menstruation take part trial asymptomatic genital infection time enrollment , cervix vagina appear normal upon pelvic examination colposcopy , determine investigator willing refrain use vaginal product object include , limited , tampon , cotton wool , rag , diaphragm , cervical cap ( vaginal barrier method ) , douche , lubricant , vibrators/dildos , nontrial vaginal ring dry agent 14 day prior enrollment duration trial willing refrain participation research trial duration trial willing provide adequate locator information trial retention purpose reachable per local standard procedure ( e.g . home visit telephone , via family close neighbor contact ( confidentiality maintain ) ) hepatitis B C negative time screen . history anaphylaxis severe allergy result angioedema , history sensitivity/allergy latex silicone pregnant breastfeeding , last pregnancy outcome within three month prior screen participate clinical research trial involve investigational market product time trial within two month prior screen history diagnosis and/or treatment sexually transmit disease within previous three month history genital tract surgery within previous two month current diagnosis sexually transmit infection ( STIs ) ( gonorrhea , chlamydia and/or trichomonas ) current vulvar vaginal symptoms/abnormalities could influence trial result history significant urogenital uterine prolapse , undiagnosed vaginal bleeding urethral obstruction , incontinence urge incontinence symptomatic genital herpes simplex virus ( HSV ) infection history genital herpetic infection current noniatrogenic pelvic/colposcopic examination finding involve deep epithelial disruption Grade 2 , 3 4 hematology , biochemistry urinalysis laboratory abnormality baseline ( screen ) , accord Division Acquired Immunodeficiency Syndrome ( DAIDS ) Table Grading Adverse Events Pap test result screening require cryotherapy , biopsy , treatment ( infection ) evaluation ; include finding atypical squamous cell undetermined significance ( ASCUS ) condition ( ) , opinion investigator , could interfere adherence trial requirement evaluation trial objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>HIV seronegativity</keyword>
</DOC>